Lifevantage Corp Stock Price, News & Analysis

LifeVantage (LFVN) reported strong Q3 fiscal 2025 results with revenue reaching $58.4 million, up 21.1% year-over-year. Net income per diluted share doubled to $0.26 from $0.13 in the prior year. The Americas region showed robust growth of 29.5%, while Asia/Pacific & Europe saw a 7.2% decline. Gross profit margin improved by 210 basis points to 81.0%. The company's MindBody GLP-1 System™ drove strong demand, and international expansion continued with launches in multiple Asian and European markets. The company declared a dividend of $0.045 per share and maintained its fiscal 2025 guidance with expected revenue between $228-235 million and adjusted EBITDA of $21-24 million.

Key metrics include adjusted EBITDA of $6.4 million (vs $5.1M year ago), cash and equivalents of $22.5 million with no debt, and operating income of $4.1 million (vs $1.9M year ago).

LifeVantage (LFVN) concluded its annual Global Convention in Salt Lake City from April 24-26, 2025, attracting over 2,000 Independent Consultants worldwide. The event, centered on the 'Drive ERA' theme, featured key business updates and product announcements.

The company highlighted its MindBody GLP-1 System™ (MB System™), now expanding to Europe, Mexico, Thailand, Australia, and New Zealand. Recent clinical studies showed the product increased GLP-1 levels by over 200% on average.

Two new AXIO product flavors were unveiled: Peach Nectarine as a permanent decaf option launching April 29, and an event-exclusive Tiger's Blood flavor. The company also announced a Q2 Sales Incentive doubling bonuses for new Senior Consultant 1 ranks and revealed Thailand as the 2026 Executive Destination Trip location.

LifeVantage (Nasdaq:LFVN), a health and wellness company focused on cellular health products, has scheduled its third quarter fiscal year 2025 financial results announcement for May 6, 2025, after market close.

The company will host an investor conference call at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) on the same day. U.S. investors can participate by dialing (877) 704-4453, while international callers should use (201) 389-0920.

A replay will be available until May 20, 2025, accessible via (844) 512-2921 (U.S.) or (412) 317-6671 (international) using confirmation code 13752773. A live webcast will be simultaneously available on the company's Investor Relations website, with a 30-day archive period.

LifeVantage (LFVN) is expanding its MindBody GLP-1 System™ (MB System™) internationally following significant success in the U.S. market, where it contributed to a 49% year-over-year increase in fiscal Q2 revenue ending December 31, 2024.

The MB System™ launched on March 15, 2025, in Japan for both Consultants and Customers, while becoming available exclusively to Consultants in Australia, New Zealand, Europe, UK, Mexico, and Thailand, with customer access starting April 25. The product is designed to naturally activate the body's GLP-1 production for metabolic health benefits.

The expansion targets the growing global GLP-1 pharmaceutical market, valued at $53.46 billion in 2024 and projected to reach $156.71 billion by 2030 with a 17.5% CAGR. LifeVantage plans to launch the MB System™ in the Philippines and Taiwan in early summer, followed by Canada later in the year.

LifeVantage (LFVN) has announced the expansion of its LV360 initiative and Evolve Compensation Plan into the Philippines, Taiwan, Hong Kong, and Singapore markets, effective March 1, 2025. This marks Phase 3 of the global rollout, following successful launches in Canada, Mexico, and Europe in February 2024, and in the US, Australia, New Zealand, and Japan in March 2023.

The Evolve Compensation Plan is structured to provide multiple income streams for Consultants through business building and product sales initiatives. The plan features early income bonuses, performance rewards, and mentorship incentives, designed to support both product-focused entrepreneurs and team builders.

CEO Steve Fife emphasized that the LV360 transformation, initiated two years ago, has been important in adapting to current direct sales industry trends and empowering Consultants with essential tools for business growth.

LifeVantage (Nasdaq: LFVN), a health and wellness company focusing on cellular-level health products, has announced a quarterly dividend payment. The company's Board of Directors has approved a cash dividend of $0.04 per share of common stock. The dividend will be paid on March 17, 2025, to stockholders of record as of the close of business on March 3, 2025.

LifeVantage (LFVN) reported strong financial results for Q2 fiscal 2025, with revenue reaching $67.8 million, up 31.3% year-over-year. The company's performance was driven by the successful launch of MindBody GLP-1 System™ in October. Key highlights include:

- Americas revenue increased 46.3%, with US revenue up 48.8%
- Asia/Pacific & Europe revenue decreased 15.5%
- Net income per diluted share was $0.19, compared to a loss of $0.05 year ago
- Adjusted EBITDA reached $6.5 million vs $3.1 million last year
- Gross profit margin improved to 80.5%

The company raised its fiscal 2025 guidance, now expecting revenue between $235-245 million, adjusted EBITDA of $21-24 million, and adjusted EPS of $0.72-0.88. A quarterly dividend of $0.04 per share was declared, payable March 17, 2025.

LifeVantage (LFVN) has completed an international in vitro cell study on its MB System™, the international formulation of the MindBody GLP-1 System™. The study examined the formula's effects on GLP-1 hormone production in specialized L-cells found in the colon. The research analyzed key genes involved in GLP-1 production and regulation, including GCG, GLP1R, DPP-4, PYY, and PPY.

The study utilized ELISA and fluorescent microscopy to evaluate the two-product system's synergistic potential, which aims to enhance GLP-1 production through L-cell activation and gut microbiome optimization. The US version of the product, launched in October, showed positive results in a 12-week human clinical trial, demonstrating a 140% average increase in GLP-1 production. The international version is scheduled for launch in March.

LifeVantage (LFVN), a health and wellness company focusing on cellular health products, has announced it will release its second quarter fiscal 2025 financial results on February 5, 2025, after market close. The company will host a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) on the same day.

Investors can participate in the live call by dialing (877) 704-4453 from the U.S. or (201) 389-0920 internationally. A replay will be available until February 19, 2025, accessible by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (international) with confirmation code 13750382. A simultaneous webcast will be available on the company's Investor Relations website, with a 30-day archive period.